I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| natural killer cell | 38 studies | 54% ± 20% | |
| CD8-positive, alpha-beta T cell | 26 studies | 46% ± 21% | |
| mature NK T cell | 17 studies | 63% ± 24% | |
| CD16-positive, CD56-dim natural killer cell, human | 15 studies | 63% ± 17% | |
| T cell | 14 studies | 34% ± 13% | |
| CD16-negative, CD56-bright natural killer cell, human | 13 studies | 30% ± 12% | |
| gamma-delta T cell | 12 studies | 45% ± 17% | |
| CD8-positive, alpha-beta memory T cell | 11 studies | 39% ± 16% | |
| effector memory CD8-positive, alpha-beta T cell | 10 studies | 44% ± 20% | |
| effector CD8-positive, alpha-beta T cell | 9 studies | 51% ± 24% | |
| effector memory CD8-positive, alpha-beta T cell, terminally differentiated | 5 studies | 76% ± 9% | |
| exhausted T cell | 5 studies | 32% ± 9% | |
| naive thymus-derived CD8-positive, alpha-beta T cell | 4 studies | 44% ± 24% | |
| CD4-positive, alpha-beta T cell | 3 studies | 42% ± 31% |
